- Home
- CYCU vs CVKD Comparison
CYCU vs CVKD Comparison
Compare CYCU & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CYCU | CVKD |
|---|---|---|
| Founded | 2017 | 2022 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 19.5M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | CYCU | CVKD |
|---|---|---|
| Price | $3.73 | $9.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | ★ 4.0M | 18.1K |
| Earning Date | 11-14-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,667,874.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.15 | $8.74 |
| 52 Week High | $2,045.10 | $22.90 |
Technical Indicators
Market Signals| Indicator | CYCU | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 54.20 | 27.16 |
| Support Level | $3.50 | $9.30 |
| Resistance Level | $5.09 | $11.29 |
| Average True Range (ATR) | 0.84 | 0.81 |
| MACD | -0.15 | -0.24 |
| Stochastic Oscillator | 26.13 | 2.43 |
Price Performance
Historical ComparisonAbout CYCU Cycurion Inc. Common Stock
Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.